Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

-701 for Pompe Disease: The Phase I/II trial in Pompe patients is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN-701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company has completed enrollment of patients in the 10 mg/kg dose cohort.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673: a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors and a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  Top-line results for both studies are expected in the second half of 2012.

  • Preclinical Programs

  • BMN-111 for Achondroplasia: BioMarin expects to file an IND in the fourth quarter of 2011 and initiate a Phase I trial in the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple additional early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and nine months ended September 30, 2011 and September 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, continge
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Present at the UBS Global Life Sciences Conference
    2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
    3. BioMarin to Present at the Baird Health Care Conference
    4. BioMarin to Present at the Wedbush Life Sciences Conference
    5. BioMarin Announces Second Quarter 2011 Financial Results
    6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
    7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
    8. BioMarin to Present at the William Blair Growth Stock Conference
    9. BioMarin to Present at the Jefferies Global Healthcare Conference
    10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
    11. BioMarin Announces First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
    (Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
    (Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
    Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
    ... 30 CEL-SCI Corporation,(Amex: CVM ) announced that ... Rodman & Renshaw 9th Annual Healthcare Conference being,held at ... The presentation,will be focused on its Phase III cancer ... to become a new first line standard of,care treatment ...
    ... Oct. 29 As a follow up to ... eliminating,Methicillin resistant Staphylococcus aureus (MRSA), the Association for,Professionals ... days next,month in Atlanta to discuss new developments ... "MRSA: The Call to Action 1 Year ...
    Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2APIC Conference to Discuss MRSA Elimination 2
    (Date:12/24/2014)... 24, 2014 (HealthDay News) -- The holidays can be a ... off by certain foods and drinks. "This is the ... trigger attacks of migraine," Dr. David Dodick, chair of the ... foundation. "It,s important to think through food and beverage ... attack," added Dodick, a professor of neurology at the Mayo ...
    (Date:12/24/2014)... say they have used human embryonic stem cells to ... While this had already been done using rodent stem ... of cells -- called primordial germ cells -- have ... the team at the University of Cambridge in England. ... of the earliest events during early mammalian development," study ...
    (Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
    (Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
    (Date:12/24/2014)... For nearly 20 years, June Cotner has been ... all of life's rites of passage. Here, she joins ... in Toasts: The Perfect Words to Celebrate Every ... by category and containing many original toasts written just ... timely tome contains sayings famous and profound, suitable and ...
    Breaking Medicine News(10 mins):Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
    ... A new study shows that smokers who think that they might ... a “ light “ or “ mild “ cigarette // might ... reduction in nicotine is minimal, and in the end, the light ... Previous studies have shown that low-yield cigarettes can be just as ...
    ... a person’s risk of developing dementia later in life, a ... recent study conducted, researchers followed nearly 1,500 participants for more ... middle age were twice as likely to develop dementia later ... blood pressure in middle age were six-times more likely to ...
    ... can avoid the risk of stroke by eating broiled or baked ... to four// times a week had 28% less risk ... who ate fish less than once a month. And people who ... their risk was lowered by 31%. However the fish cooked had ...
    ... time, a drug seems to slightly delay the progress ... studies have shown that without treatment, about 10 percent ... will progress to Alzheimer’s disease each year. However, not ... ,Researchers compared vitamin E, the Alzheimer’s treatment drug ...
    ... patients fare better after having a procedure to open clogged ... from a recent study. The study, conducted in Taiwan, looked ... of about 870 men and about 160 women who underwent ... While both sexes had about the same success rate for ...
    ... lining the uterus grow outside of the uterus and ... The condition can cause bleeding, pain and discomfort. Women ... to suffer from the painful condition known as endometriosis, ... diagnosed with endometriosis, comparing their results to 504 other ...
    Cached Medicine News:
    Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
    ... hand throttle. Accepts all 1000 and 2000 ... hose 9000-000, or existing hose with Microaire ... or existing hose with Linvatec/Hall connector (1000-200). ... hose with 3M connector (1000-300). , 10ft ...
    Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
    Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
    Medicine Products: